ESR1 and breast cancer: Our ChIP-qPCR results confirmed that the ENCODE ZMIZ1 ChIP-seq result was generalisable to our breast cancer model and that degrading ER with fulvestrant led to the loss of ZMIZ1 binding but had no effect on our IgG control ChIP (Fig. 3C).